metaEvidence - overview


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
mGC or mGEJC - M - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 negative
versus Standard of Care (SoC)
	avelumab alone vs. Standard of Care (SoC)	1	none	inconclusive results for: deaths (OS); progression or deaths (PFS); DCR; DOR; objective responses (ORR); AE (any grade); AE (grade 3-4); AE leading to death (grade 5); SAE (any grade); STRAE (any grade); TRAE leading to death (grade 5)	suggested 57 % decrease in AE leading to treatment discontinuation (any grade) but the degree if certainty is unassessable suggested 53 % decrease in TRAE (any grade) but the degree if certainty is unassessable suggested 69 % decrease in TRAE (grade 3-4) but the degree if certainty is unassessable suggested 69 % decrease in TRAE leading to discontinuation (any grade) but the degree if certainty is unassessable	-
mGC or mGEJC - M - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
	avelumab alone vs. Standard of Care (SoC)	1	none	inconclusive results for: deaths (OS); progression or deaths (PFS)	-	-